Comparison of Pantoprazole and Ranitidine in Dyspepsia
The H0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.
The H1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.|
- Visual Analogue Scale Score [ Time Frame: 30th and 60th minutes ] [ Designated as safety issue: No ]The investigators are measuring the change of pain from the baseline to the 30th and 60th minutes by visual anologue scale (VAS). Visual Analogue Scale measurement is between 0 (no pain) and 100 (worst pain). A decrease of 13 or 16 mm in VAS score is accepted as a minimum clinically significant change in pain.
- Need for Additional Drug [ Time Frame: 60 th minute ] [ Designated as safety issue: No ]The investigators are measuring the need for additional drug at the end of 60 minutes.
|Study Start Date:||October 2012|
|Study Completion Date:||January 2013|
|Primary Completion Date:||January 2013 (Final data collection date for primary outcome measure)|
Intravenous pantoprazole 40 mg flacon
Other Name: Pantpas
Active Comparator: ranitidine
Intravenous ranitidine 50 mg
Other Name: Ulcuran
Dyspepsia is one of the common complaints in emergency department. Proton pomp inhibitors, H2 receptor blockers and anti-acids are common drugs for treating dyspepsia in emergency department. However there is no study in the emergency department comparing the effectiveness of these drugs. So the investigators planned this study which drug is effective in these patients in order to provide a cost-effective treatment in dyspeptic patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737840
|Antalya, Turkey, 07050|
|Study Director:||Cenker Eken, Proffesor||Akdeniz University|